SOSTDC1 downregulation in CD4+ T cells confers protection against obesity-induced insulin resistance

Summary: Adipose-resident T cells play a crucial role in the development of obesity-induced insulin resistance. However, the specific mechanisms, particularly those involving non-immune cytokines, remain unclear. Here, we report significantly elevated levels of sclerostin domain-containing protein 1...

Full description

Saved in:
Bibliographic Details
Main Authors: Dehai Li, Jing Zhu, Mingyue Zhang, Qiping Shi, Rong Guo, Daming Zhang, Pei Zheng, Hua Zhang, Guangqiang Li, Jie Wu, Guodong Sun, Qiong Wen, Jingyi Tan, Zonghua Liu, Xindong Liu, Hengwen Yang, Hongyun Lu, Guangchao Cao, Zhinan Yin, Qian Wang
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Cell Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124725002670
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary: Adipose-resident T cells play a crucial role in the development of obesity-induced insulin resistance. However, the specific mechanisms, particularly those involving non-immune cytokines, remain unclear. Here, we report significantly elevated levels of sclerostin domain-containing protein 1 (SOSTDC1) in individuals with type 2 diabetes (T2D), showing positive correlations with fasting glucose and HbA1c. T cell-specific Sostdc1-deficient mice exhibit resistance to age-induced adipose lipid accumulation and glucose dysregulation at 12 months and protect against obesity-induced insulin resistance without affecting proinflammatory macrophage infiltration or adipose inflammation. Mechanistically, SOSTDC1 disrupts the lipid balance in adipocytes by promoting lipogenesis and inhibiting lipolysis through the LRP5/6-β-catenin pathway. Furthermore, T cell receptor (TCR) signaling significantly amplifies SOSTDC1 secretion in CD4+ T cells. In summary, our study uncovers an additional mechanism by which T cells contribute to obesity and insulin resistance, suggesting that inhibiting SOSTDC1 could be a promising immunotherapeutic strategy for metabolic disorders.
ISSN:2211-1247